Nuvectis Pharma
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +106.4% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 7.8% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Performance
Key statistics
Price & volume
- Prev close
- 19.84
- Open
- 19.60
- Day range
- 19.02 - 20.18
- Avg price
- 19.36
- Volume
- 301.61K
- Turnover
- 5.84M
- Turnover ratei
- 1.31%
- Volume ratioi
- 1.50
- Amplitudei
- 5.85%
- 52-week rangei
- 5.77 - 29.28
Valuation
- P/Ei
- -14.69
- P/E (TTM)i
- -9.70
- P/Bi
- 5.26
- EPSi
- -1.32
- Book value / shi
- 3.68
- Net profit
- -45.39M
- Net assets
- 126.65M
Share structure
- Market cap
- 666.80M
- Float capi
- 446.17M
- Shares out
- 34.39M
- Float sharesi
- 23.01M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2022-02-04
33.8% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-246.23K net over the window
Short interest
- Shares short
- 2.54M
- % of floati
- 7.80%
- Days to coveri
- 15.16
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Nuvectis Pharma (NVCT)?
Nuvectis Pharma last traded at 19.39. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Nuvectis Pharma's market cap?
About 666.80M.
What is the P/E ratio of Nuvectis Pharma?
The trailing twelve-month P/E is -9.70. The Valuation tab shows it against the stock's own five-year range.
Does Nuvectis Pharma pay a dividend?
Nuvectis Pharma does not currently pay a regular dividend.
Is Nuvectis Pharma a buy according to analysts?
The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 34.50, which implies 77.9% upside from the current price. This is not investment advice.
What is Nuvectis Pharma's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Nuvectis Pharma a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Nuvectis Pharma discussion 0 comments